Thorac Cardiovasc Surg
DOI: 10.1055/a-2205-2479
Original Thoracic

Single-Stage Surgical Procedure for Patients with Primary Esophageal and Lung Cancers

1   Department of Cardiothoracic Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
,
Hu Fengqing
1   Department of Cardiothoracic Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
,
Xie Xiao
1   Department of Cardiothoracic Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
,
Zhang Xuefeng
2   Department of Radiology, The First Affiliated Hospital, Naval Medical University, Shanghai, China
,
Bi Rui
1   Department of Cardiothoracic Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
› Author Affiliations

Abstract

Background The aim of this study was to evaluate the safety and feasibility of simultaneous surgery for patients with primary esophageal and lung cancers.

Methods Patients with primary esophageal and lung cancers who underwent simultaneous surgical procedures between January 2016 and January 2022 were retrospectively analyzed. The data of patients who underwent esophagectomy and lobectomy (group EL) were compared with those of patients who underwent esophagectomy and sublobar resection (group ES).

Results A total of 21 patients were included with an average age of 64.62 ± 5.24 years. Group EL contained 8 patients and group ES contained 13 patients. All procedures were completed uneventfully with a mean operative time of 251.19 ± 66.93 minutes. Pulmonary complications occurred in six (28.57%) patients. Other complications included anastomotic leakage in 1 patient, pleural effusion requiring drainage in 8 patients, atrial fibrillation in 2 patients, and incision infection in 1 patient. All patients were followed up for 30.23 ± 21.82 months. During the follow-up period, nine patients had a recurrence of cancer and died of tumor progression, and one patient died of a tracheothoracogastric fistula. Complications and mortality in group EL did not increase when compared to those in group ES.

Conclusion It is safe and feasible to perform a single-stage surgical procedure for patients with primary esophageal and lung cancers. Simultaneous esophagectomy and lobectomy did not increase postoperative complications or mortality compared with esophagectomy and sublobar resection.



Publication History

Received: 18 July 2023

Accepted: 06 November 2023

Accepted Manuscript online:
07 November 2023

Article published online:
21 December 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Fékété F, Sauvanet A, Kaisserian G. et al. Associated primary esophageal and lung carcinoma: a study of 39 patients. Ann Thorac Surg 1994; 58 (03) 837-842
  • 2 Matsubara T, Ueda M, Takahashi T, Nakajima T, Nishi M. Surgical treatment of cancer of the thoracic esophagus in association with a major pulmonary operation. J Am Coll Surg 1997; 185 (06) 520-524
  • 3 Fukuda H, Ogino N, Takao T, Kobayashi S, Kido T. A case report of synchronous double cancer of the lung and esophagus. Nihon Kyobu Geka Gakkai Zasshi 1990; 38 (06) 1053-1058
  • 4 Li F, Shao K, Xue Q, He J. Clinical observation of 16 patients with synchronous esophageal cancer and lung cancer treated with simultaneous esophagus and lung resection. Zhonghua Yi Xue Za Zhi 2011; 91 (15) 1064-1066
  • 5 Wang XX, Liu TL, Wang P, Li J. Is surgical treatment of cancer of the gastric cardia or esophagus associated with a concurrent major pulmonary operation feasible? One center's experience. Chin Med J (Engl) 2012; 125 (02) 193-196
  • 6 Raymond DP, Seder CW, Wright CD. et al. Predictors of major morbidity or mortality after resection for esophageal cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database Risk Adjustment Model. Ann Thorac Surg 2016; 102 (01) 207-214
  • 7 Yoshida N, Watanabe M, Baba Y. et al. Risk factors for pulmonary complications after esophagectomy for esophageal cancer. Surg Today 2014; 44 (03) 526-532
  • 8 Tajima T, Haruki S, Takiguchi N. et al. Surgical treatment for synchronous double cancer of the thoracic esophagus and lung. Kyobu Geka 2017; 70 (10) 822-826
  • 9 Ishii H, Sato H, Tsubosa Y, Kondo H. Treatment of double carcinoma of the esophagus and lung. Gen Thorac Cardiovasc Surg 2008; 56 (03) 126-130
  • 10 Fang W, Kato H, Tachimori Y, Igaki H, Sato H, Daiko H. Analysis of pulmonary complications after three-field lymph node dissection for esophageal cancer. Ann Thorac Surg 2003; 76 (03) 903-908
  • 11 Ferguson MK, Celauro AD, Prachand V. Prediction of major pulmonary complications after esophagectomy. Ann Thorac Surg 2011; 91 (05) 1494-1500 , discussion 1500–1501
  • 12 Zingg U, Smithers BM, Gotley DC. et al. Factors associated with postoperative pulmonary morbidity after esophagectomy for cancer. Ann Surg Oncol 2011; 18 (05) 1460-1468
  • 13 Ohi M, Toiyama Y, Omura Y. et al. Risk factors and measures of pulmonary complications after thoracoscopic esophagectomy for esophageal cancer. Surg Today 2019; 49 (02) 176-186
  • 14 Paul DJ, Jamieson GG, Watson DI, Devitt PG, Game PA. Perioperative risk analysis for acute respiratory distress syndrome after elective oesophagectomy. ANZ J Surg 2011; 81 (10) 700-706
  • 15 Avendano CE, Flume PA, Silvestri GA, King LB, Reed CE. Pulmonary complications after esophagectomy. Ann Thorac Surg 2002; 73 (03) 922-926
  • 16 Brunelli A, Xiumé F, Refai M. et al. Evaluation of expiratory volume, diffusion capacity, and exercise tolerance following major lung resection: a prospective follow-up analysis. Chest 2007; 131 (01) 141-147
  • 17 Cukic V. Reduction of pulmonary function after surgical lung resections of different volume. Med Arh 2014; 68 (04) 231-235
  • 18 Zhou C, Zhang L, Wang H. et al. Superiority of minimally invasive oesophagectomy in reducing in-hospital mortality of patients with resectable oesophageal cancer: a meta-analysis. PLoS One 2015; 10 (07) e0132889
  • 19 van Workum F, van der Maas J, van den Wildenberg FJ. et al. Improved functional results after minimally invasive esophagectomy: intrathoracic versus cervical anastomosis. Ann Thorac Surg 2017; 103 (01) 267-273
  • 20 Singhal S, Kailasam A, Akimoto S, Masuda T, Bertellotti C, Mittal SK. Simple technique of circular stapled anastomosis in Ivor Lewis esophagectomy. J Laparoendosc Adv Surg Tech A 2017; 27 (03) 288-294
  • 21 Fabiani I, Colombo A, Bacchiani G, Cipolla CM, Cardinale DM. Incidence, management, prevention and outcome of post-operative atrial fibrillation in thoracic surgical oncology. J Clin Med 2019; 9 (01) 37
  • 22 Semeraro GC, Meroni CA, Cipolla CM, Cardinale DM. Atrial fibrillation after lung cancer surgery: prediction, prevention and anticoagulation management. Cancers (Basel) 2021; 13 (16) 4012
  • 23 Strand TE, Rostad H, Møller B, Norstein J. Survival after resection for primary lung cancer: a population based study of 3211 resected patients. Thorax 2006; 61 (08) 710-715
  • 24 Altorki NK, Yip R, Hanaoka T. et al; I-ELCAP Investigators. Sublobar resection is equivalent to lobectomy for clinical stage 1A lung cancer in solid nodules. J Thorac Cardiovasc Surg 2014; 147 (02) 754-762 , Discussion 762–764
  • 25 Cao J, Yuan P, Wang Y. et al. Survival rates after lobectomy, segmentectomy, and wedge resection for non-small cell lung cancer. Ann Thorac Surg 2018; 105 (05) 1483-1491
  • 26 Kim SJ, Lee YJ, Park JS. et al. Changes in pulmonary function in lung cancer patients after video-assisted thoracic surgery. Ann Thorac Surg 2015; 99 (01) 210-217
  • 27 Fiorelli A, Caronia FP, Daddi N. et al. Sublobar resection versus lobectomy for stage I non-small cell lung cancer: an appropriate choice in elderly patients?. Surg Today 2016; 46 (12) 1370-1382
  • 28 Saji H, Okada M, Tsuboi M. et al; West Japan Oncology Group and Japan Clinical Oncology Group. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet 2022; 399 (10335): 1607-1617